(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

A1

(19) World Intellectual Property Organization
International Bureau

G00002

(43) International Publication Date
7 February 2002 (07.02.2002)

PCT

(10) International Publication Number
WO 02/09707 A1

(51) International Patent Classification[7]: A61K 31/435, A61P 25/04

(21) International Application Number: PCT/DK01/00521

(22) International Filing Date: 31 July 2001 (31.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2000 01154 31 July 2000 (31.07.2000) DK

(71) Applicant *(for all designated States except US)*: **NYCOMED DANMARK A/S** [DK/DK], Langebjerg 1, P.O Box 88, DK-4000 Roskilde (DK).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GRARUP, Jesper** [DK/DK]; Låddenhøj 87, DK-4000 Roskilde (DK). **NIELSEN, Hanne, Wulff** [DK/DK], Valdemarsgade 21, DK-5700 Svendborg (DK)

(74) Agent: **PLOUGMANN, VINGTOFT & PARTNERS A/S**, Sankt Annæ Plads 11, PO Box 3007, DK-1021 Copenhagen K (DK).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EC, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: FENTANYL COMPOSITION FOR NASAL ADMINISTRATION

162162

WO 02/09707 A1



(57) Abstract: The treatment of acute pain with a sufficient dosage by intranasal administration of fentanyl results in a time to onset of action comparable to intravenous administration and a significantly faster onset of action than nasal titration of fentanyl. The nasal administration of a sufficient amount of fentanyl to obtain pain relief has lower maximum plasma concentrations comparable to intravenous administration and results in lower rates of adverse events like respiratory depression, nausea and vomiting. Compositions fur use in the method are also disclosed

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette